Screening Guidelines and Programs for Cervical Cancer Control in Countries of Different Economic Groups: A Narrative Review
- PMID: 37519623
- PMCID: PMC10381098
- DOI: 10.7759/cureus.41098
Screening Guidelines and Programs for Cervical Cancer Control in Countries of Different Economic Groups: A Narrative Review
Abstract
Screening guidelines and practices differ according to resource availability and continually update as scientific developments take place. In this article, we have reviewed screening guidelines and programs for cervical cancer prevention in selected countries belonging to different economic groups viz high income, middle income, and low income. We have selected six countries - the United States of America (USA), the United Kingdom (UK), India, South Africa, Bangladesh, and Malawi. Considerable differences are observed across the health systems. Countries with established screening guidelines complemented by organised nationwide programs or insurance practices have much better screening rates. Human Papilloma Virus (HPV) DNA testing is currently the test of choice in the majority of settings for cervical cancer screening due to its higher sensitivity (up to 90-100%) and longer screening intervals (three to five years). It is also cost-effective, less dependent on operator expertise, and suitable for all settings as compared to a Pap smear test or visual inspection with acetic acid (VIA). Self-sampling of HPV can further help to improve screening coverage by increasing opportunities of reaching to women who would otherwise not participate in screening programs. Resource-constrained countries recommend VIA-based screening in their national programs due to its low cost. The share of cervical cancer is higher in middle and low-income countries as they have lower screening coverage, compared to high-income countries. The main barriers faced in the implementation of the program in low-income countries (LICs) are pertaining to the health system, patient-specific challenges, and healthcare provider-specific challenges.
Keywords: barriers; cervical cancer; guidelines; health system challenges; implementation; program; screening.
Copyright © 2023, Sharma et al.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures

Similar articles
-
Current Status and Future Perspectives of Molecular Prevention Strategies for Cervical Cancers.Indian J Surg Oncol. 2020 Dec;11(4):752-761. doi: 10.1007/s13193-019-00910-z. Epub 2019 Mar 18. Indian J Surg Oncol. 2020. PMID: 33299288 Free PMC article. Review.
-
Optimizing high risk HPV-based primary screening for cervical cancer in low- and middle-income countries: opportunities and challenges.Minerva Ginecol. 2019 Oct;71(5):365-371. doi: 10.23736/S0026-4784.19.04468-X. Minerva Ginecol. 2019. PMID: 31698891 Review.
-
Towards the elimination of cervical cancer in low-income and lower-middle-income countries: modelled evaluation of the effectiveness and cost-effectiveness of point-of-care HPV self-collected screening and treatment in Papua New Guinea.BMJ Glob Health. 2022 Mar;7(3):e007380. doi: 10.1136/bmjgh-2021-007380. BMJ Glob Health. 2022. PMID: 35241461 Free PMC article.
-
A Family-Centered Sexual Health Intervention to Promote Cervical Cancer Screening Uptake Among Low-Income Rural Women in India: Protocol for a Community-Based Mixed Methods Pilot Study.JMIR Res Protoc. 2022 Sep 8;11(9):e35093. doi: 10.2196/35093. JMIR Res Protoc. 2022. PMID: 36074549 Free PMC article.
-
Anal dysplasia screening: an evidence-based analysis.Ont Health Technol Assess Ser. 2007;7(4):1-43. Epub 2007 Jun 1. Ont Health Technol Assess Ser. 2007. PMID: 23074504 Free PMC article.
Cited by
-
Principles for Service Delivery: Best Practices for Cervical Screening for Women with Disabilities.Int J Womens Health. 2024 Apr 18;16:679-692. doi: 10.2147/IJWH.S428144. eCollection 2024. Int J Womens Health. 2024. PMID: 38650833 Free PMC article. Review.
-
Yield of endocervical curettage in detecting cervical intraepithelial neoplasia grade 2 or higher during colposcopy: A prospective, cross-sectional study.Int J Gynaecol Obstet. 2025 Apr;169(1):105-111. doi: 10.1002/ijgo.16074. Epub 2024 Dec 4. Int J Gynaecol Obstet. 2025. PMID: 39629968 Free PMC article.
-
Addressing Global Disparities in Cervical Cancer Burden: A Narrative Review of Emerging Strategies.Curr HIV/AIDS Rep. 2025 Feb 21;22(1):18. doi: 10.1007/s11904-025-00727-2. Curr HIV/AIDS Rep. 2025. PMID: 39979520 Free PMC article. Review.
-
Findings and Challenges in Replacing Traditional Uterine Cervical Cancer Diagnosis with Molecular Tools in Private Gynecological Practice in Mexico.Viruses. 2024 May 31;16(6):887. doi: 10.3390/v16060887. Viruses. 2024. PMID: 38932179 Free PMC article.
-
Advancing Cervical Cancer Prevention Equity: Innovations in Self-Sampling and Digital Health Technologies Across Healthcare Settings.Diagnostics (Basel). 2025 May 6;15(9):1176. doi: 10.3390/diagnostics15091176. Diagnostics (Basel). 2025. PMID: 40361993 Free PMC article. Review.
References
-
- Globocan: Cancer today, International agency for research on cancer. [ May; 2023 ];https://gco.iarc.fr/today/home 2020 21:2023.
-
- Cervical cancer in low and middle-income countries. Hull R, Mbele M, Makhafola T, et al. https://pubmed.ncbi.nlm.nih.gov/32782524/ Oncol Lett. 2020;20:2058–2074. - PMC - PubMed
-
- Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Satterwhite CL, Torrone E, Meites E, et al. Sex Transm Dis. 2013;40:187–193. - PubMed
-
- HPV vaccine development: a case study of prevention and politics. Grimes JL. https://iubmb.onlinelibrary.wiley.com/doi/full/10.1002/bmb.2006.49403402148. Biochem Mol Biol Educ. 2006;34:148–154. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials